InMode Ltd. (NASDAQ:INMD) Shares Sold by Marco Investment Management LLC

Marco Investment Management LLC decreased its holdings in shares of InMode Ltd. (NASDAQ:INMD) by 4.3% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 35,975 shares of the healthcare company’s stock after selling 1,600 shares during the quarter. Marco Investment Management LLC’s holdings in InMode were worth $610,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Carmel Capital Partners LLC raised its stake in shares of InMode by 6.9% during the third quarter. Carmel Capital Partners LLC now owns 11,511 shares of the healthcare company’s stock valued at $195,000 after purchasing an additional 741 shares during the period. ProShare Advisors LLC lifted its holdings in InMode by 8.5% in the 1st quarter. ProShare Advisors LLC now owns 13,920 shares of the healthcare company’s stock worth $301,000 after buying an additional 1,094 shares in the last quarter. Meritage Portfolio Management boosted its position in InMode by 9.5% in the 3rd quarter. Meritage Portfolio Management now owns 14,765 shares of the healthcare company’s stock valued at $250,000 after buying an additional 1,284 shares during the last quarter. Cetera Advisors LLC grew its stake in shares of InMode by 8.9% during the first quarter. Cetera Advisors LLC now owns 17,028 shares of the healthcare company’s stock valued at $368,000 after acquiring an additional 1,394 shares in the last quarter. Finally, Inspire Advisors LLC increased its position in shares of InMode by 9.0% during the second quarter. Inspire Advisors LLC now owns 21,433 shares of the healthcare company’s stock worth $391,000 after acquiring an additional 1,778 shares during the last quarter. 68.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

INMD has been the subject of a number of analyst reports. BTIG Research started coverage on InMode in a report on Thursday, October 17th. They issued a “buy” rating and a $25.00 price target for the company. Barclays decreased their price target on shares of InMode from $29.00 to $27.00 and set an “overweight” rating for the company in a research report on Monday, October 14th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of InMode in a research note on Thursday, October 31st. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average target price of $22.60.

InMode Trading Up 2.9 %

Shares of NASDAQ INMD opened at $19.02 on Friday. The business has a 50 day simple moving average of $17.40 and a 200-day simple moving average of $17.46. InMode Ltd. has a twelve month low of $14.87 and a twelve month high of $26.80. The company has a market capitalization of $1.60 billion, a price-to-earnings ratio of 10.28 and a beta of 2.15.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.